{"filing":{"accession_number":"0001213900-26-068264","cik":"0001604464","ticker":"ATRA","company_name":"Atara Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"ea0294561-8k_atara.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1604464/000121390026068264/ea0294561-8k_atara.htm"},"events":[{"id":10811,"run_id":9486,"accession_number":"0001213900-26-068264","anchor_item_number":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses two distinct events under Item 5.02 and Item 5.07. The most salient event is the appointment of Brian Cherry as a Class I director and Audit Committee member effective June 11, 2026, with an initial equity award of 24,000 RSUs vesting over three years. While the filing also reports shareholder vote results (Item 5.07), the appointment of a new board member is the primary material action disclosed and represents a change in the company's governance structure.","company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":7218,"accession_number":"0001213900-26-068264","item_number":null,"item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses two distinct events under Item 5.02 and Item 5.07. The most salient event is the appointment of Brian Cherry as a Class I director and Audit Committee member effective June 11, 2026, with an initial equity award of 24,000 RSUs vesting over three years. While the filing also reports shareholder vote results (Item 5.07), the appointment of a new board member is the primary material action disclosed and represents a change in the company's governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T02:19:13.451504+00:00","company_name":"Atara Biotherapeutics, Inc.","ticker":"ATRA","filing_date":"2026-06-12"}]}